Advanced search
Publication Cover
Expert Review of Vaccines Volume 13, 2014 - Issue 2
Submit an article Journal homepage
254
Views
40
CrossRef citations to date
0
Altmetric
Perspectives

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication

Kimberly M ThompsonKid Risk, Inc., 10524 Moss Park Rd., Ste. 204-364, Orlando, FL 32832, USACorrespondence[email protected]
&
Radboud J Duintjer TebbensKid Risk, Inc., 10524 Moss Park Rd., Ste. 204-364, Orlando, FL 32832, USA
Pages 221-234 | Published online: 04 Dec 2013

References

  • Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: Perspectives from modeling and prerequisites for OPV cessation. Expert Rev. Vaccines 11(4), 449–459 (2012).
  • Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Kim JH, Cochi SL. Pre-eradication national vaccine policy options for poliovirus infection and disease control. Risk Anal. 33(4), 516–543 (2013).
  • Estivariz C, Pallansch MA, Anand A et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr. Opin. Virol. 3, 309–315 (2013).
  • World Health Organization. Transmission of wild poliovirus type 2: Apparent global interruption. Wkly Epidemiol. Record. 76, 95–97 (2001).
  • Duintjer Tebbens RJ, Pallansch MA, Kim JH et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses. Risk Anal. 33(4), 680–702 (2013).
  • WHO. Global Polio Eradication Initiative: Polio Eradication and Endgame Strategic Plan (2013–2018). Report No.: WHO/POLIO/13.02, Geneva, Switzerland 2013.
  • World Health Organization: Meeting of the Strategic Advisory Group of Experts on immunization. April 2012 — conclusions and recommendations. Wkly Epidemiol. Record 21, 201–216 (2012).
  • World Health Organization: Meeting of the Strategic Advisory Group of Experts on immunization. November 2012: Conclusions and recommendations. Wkly Epidemiol. Record 88, 1–16 (2013).
  • Thompson KM. Modeling poliovirus risks and the legacy of polio eradication. Risk Anal. 33(4), 505–515 (2013).
  • World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution41.28). World Health Organization, Geneva, Switzerland 1988.
  • Anis E, Kopel E, Singer S et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. 18, 20586 (2013).
  • Eichner M, Dietz K. Eradication of poliomyelitis: When can one be sure that polio virus transmission has been terminated? Am. J. Epidemiol. 143(8), 816–822 (1996).
  • Kalkowska D, Duintjer Tebbens RJ, Thompson KM. The probability of undetected wild poliovirus circulation after apparent global interruption of transmission. Am. J. Epidemiol. 175(9), 936–949 (2012).
  • Resik S, Tejeda A, Sutter RW et al. Priming after a fractional dose of inactivated poliovirus vaccine. N. Engl. J. Med. 368(5), 416–424 (2013).
  • Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Medscape J. Med. 10(8), 190 (2008).
  • Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 33(4), 647–663 (2013).
  • Thompson KM, Wallace GS, Duintjer Tebbens RJ et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep. 127(1), 23–37 (2012).
  • Resik S, Tejeda A, Lago PM et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J. Infect. Dis. 201(9), 1344–1352 (2011).
  • Mohammed AJ, Al Awaidy S, Bawikar S et al. Fractional doses of inactivated poliovirus vaccine in Oman. N. Engl. J. Med. 362(25), 2351–2359 (2010).
  • Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int. J. Infect. Dis. 16(2), e110–e116 (2012).
  • Sutter RW, Cáceres VM, Más Lago P. The role of routine immunization in the post-certification era. Bull. World Health Organ. 82(1), 31–38 (2004).
  • Plotkin SA, Vidor E. Poliovirus vaccine -- inactivated. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA ( Eds). Saunders Elsevier, USA 605–630 (2008).
  • Duintjer Tebbens RJ, Pallansch MA, Chumakov KM et al. Expert review on poliovirus immunity and transmission. Risk Anal. 33(4), 544–605 (2013).
  • Duintjer Tebbens RJ, Pallansch MA, Chumakov KM et al. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Anal. 33(4), 606–646 (2013).
  • Mateen FJ, Shinohara RT, Sutter RW. Oral and inactivated poliovirus vaccines in the newborn: A review. Vaccine 31(21), 2517–2524 (2013).]
  • World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol. Record 85(23), 213–228 (2010).
  • Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 23(4), 703–749 (2013)
  • Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J. Infect. Dis. (2014) ( In Press).
  • Kalkowska D, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J. Infect. Dis. (2014) ( In Press).
  • Alexander LN, Seward JF, Santibanez TA et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292(14), 1696–1701 (2004).
  • Pan American Health Organization: Brazil’s Experience with the Development of a Vaccine-Wastage Evaluation System. Pan American Health Organization Immunization Newsletter. 34, 1–8 (2012).
  • Thompson KM, Duintjer Tebbens RJ, Pallansch MA et al. The risks, costs, and benefits of future global policies for managing polioviruses. Am. J. Public Health 98(7), 1322–1330 (2008).
  • WHO Policy Statement. The Use of Opened Multi-Dose Vials of Vaccine in Subsequent Immunization Sessions. WHO/V&B/00.09, WHO, Geneva, Switzerland.
  • Drain PK, Nelson CM, Lloyd JS. Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries. Bull. World Health Organ. 81, 726–731 (2003).
  • Lee BY, Norman BA, Assi TA et al. Single versus multi-dose vaccine vials: An economic computational model. Vaccine 28, 5292–5300 (2010).
  • Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J. Infect. Dis. 175, s228–s234 (1997).
  • World Health Organization Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the gambia, oman, and thailand. Who Collaborative Study Group On Oral And Inactivated Poliovirus Vaccines. Bull. World Health Organ. 74, 253–268 (1996).
  • Parent du Chatelet I, Merchant AT, Fisher-Hoch S et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 21, 1710–1718 (2003).
  • Swartz TA, Handsher R, Manor Y et al. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis. Vaccine 16, 2090–2095 (1998).
  • Halsey NA, Blatter M, Bader G et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatr. Infect. Dis. J. 16, 675–679 (1997).
  • Vogel FR, Hem SL. Immunologic adjuvants. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA ( Eds). Saunders Elsevier, USA 59–71 (2008).
  • Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 29, 644–649 (2011).
  • Simizu B, Abe S, Yamamoto H et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 34(2), 151–154 (2006).
  • Liao G, Li R, Li C et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, positive-controlled trial. J. Infect. Dis. 205(2), 237–243 (2012).
  • World Health Organization: WHO global action plan for laboratory containment of wild polioviruses (2nd Edition). Report No.: WHO/V&B/03.11, WHO, Geneva, Switzerland 2004.
  • Duintjer Tebbens RJ, Sangrujee N, Thompson KM. The costs of polio risk management policies after eradication. Risk Anal. 26(6), 1507–1531 (2006).
  • Jefferson R, Rudin M, DiPietranonj C. Systematic review of the effects of pertussis vaccines in children. Vacccine 21, 2003–2014 (2003).
  • Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369–393 (2009).
  • Naito S, Ito Y, Kiyohara T, Kataoka M, Ochiai M, Takada K. Antigen-loaded dissolving microneedle array as a novel tool for percutaneous vaccination. Vaccine 30(6), 1191–1197 (2012).
  • World Health Organization: Monitoring vaccine wastage at the country level: guidelines for programme managers. Report No.: WHO/V&B/03.18, World Health Organization, Geneva, Switzerland 2003.
  • Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann. Rev. Microbiol. 59, 587–635 (2005).
  • Duintjer Tebbens RJ, Pallansch MA, Kew OM et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 26(6), 1471–1505 (2006).
  • Collett MS, Neyts J, Modlin JF. A case for developing antiviral drugs against polio. Antiviral Res. 79(3), 179–187 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.